锕锕锕锕锕锕～再深点+在线观看,痛痛痛痛痛痛疼疼色板推特,天天碰天天爱天天摸,成人18毛片女人

您好，歡迎來(lái)到上海士研管理咨詢(xún)有限公司
產(chǎn)業(yè)峰會(huì) 演講局 專(zhuān)家智庫(kù)服務(wù) 峰會(huì)活動(dòng)服務(wù) 整合營(yíng)銷(xiāo)服務(wù)
  • 產(chǎn)業(yè)峰會(huì)：
    以專(zhuān)業(yè)團(tuán)隊(duì)對(duì)產(chǎn)業(yè)和市場(chǎng)客觀詳實(shí)地調(diào)研為前提，擁有戰(zhàn)略性、系統(tǒng)性、全球性的基因，匯集了領(lǐng)導(dǎo)者關(guān)注的熱點(diǎn)話題與領(lǐng)袖代表，為您提供“一站式”的對(duì)話、分享、社交平臺(tái)!
  • 演講局：
    致力于為全球企業(yè)和機(jī)構(gòu)提供主題演講家、高管大師班、董事會(huì)顧問(wèn)，每項(xiàng)服務(wù)都提供了一種更深入、更具互動(dòng)性的體驗(yàn)，尤其是針對(duì)較小的精選受眾和關(guān)鍵個(gè)人。我們擁有最具影響力的商業(yè)領(lǐng)袖和頂級(jí)專(zhuān)家的資源，他們是各自領(lǐng)域的最杰出的代表。我們的團(tuán)隊(duì)由經(jīng)驗(yàn)豐富的演講和活動(dòng)經(jīng)理組成，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 專(zhuān)家智庫(kù)服務(wù)：
    中國(guó)領(lǐng)先的行業(yè)專(zhuān)家知識(shí)信息服務(wù)供應(yīng)商，為需要專(zhuān)業(yè)洞見(jiàn)的商業(yè)決策者匹配具有一手經(jīng)驗(yàn)的行業(yè)專(zhuān)家，助力他們以更加明確的目標(biāo)和堅(jiān)定的信心做出決策。我們有60萬(wàn)余名專(zhuān)家顧問(wèn)遍布二十多個(gè)行業(yè)，而且每天還在增加！
  • 峰會(huì)活動(dòng)服務(wù)：
    致力于成為全球最專(zhuān)業(yè)的產(chǎn)業(yè)峰會(huì)活動(dòng)提供商，為企業(yè)和機(jī)構(gòu)的產(chǎn)業(yè)性峰會(huì)活動(dòng)提供一站式專(zhuān)業(yè)服務(wù)，包括調(diào)研策劃、定制邀請(qǐng)、營(yíng)銷(xiāo)推廣、運(yùn)營(yíng)組織、項(xiàng)目管理、直播與數(shù)字化會(huì)議等，每項(xiàng)服務(wù)都由經(jīng)驗(yàn)豐富的專(zhuān)業(yè)團(tuán)隊(duì)匹配長(zhǎng)期沉淀的產(chǎn)業(yè)資源予以卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 整合營(yíng)銷(xiāo)服務(wù)：
    致力于成為全球領(lǐng)先的2B營(yíng)銷(xiāo)服務(wù)機(jī)構(gòu)，聚焦產(chǎn)業(yè)高端活動(dòng)、內(nèi)容、渠道的建設(shè)與沉淀，為客戶(hù)提供一站式整合營(yíng)銷(xiāo)解決方案，助力企業(yè)線上線下獲客與品牌筑造。我們深信專(zhuān)業(yè)團(tuán)隊(duì)匹配產(chǎn)業(yè)資源帶來(lái)卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
嘉賓信息
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： CSO & 總經(jīng)理
所屬公司： 圣諾醫(yī)藥
個(gè)人簡(jiǎn)介：
楊博士從事核酸創(chuàng)新藥物研發(fā)工作30多年。在加入圣諾前，他參與并創(chuàng)建兩家開(kāi)發(fā)核酸藥品的美國(guó)生物科技公司。他曾經(jīng)擔(dān)任過(guò)多家國(guó)際科技公司的顧問(wèn)，是美國(guó)國(guó)立衛(wèi)生研究院三個(gè)項(xiàng)目組的評(píng)審專(zhuān)家，八家國(guó)際期刊的審稿人， 2008-2018年被美國(guó)和國(guó)內(nèi)雙一流大學(xué)聘為兼職教授。楊博士作為新藥項(xiàng)目研發(fā)總負(fù)責(zé)人（PI），在過(guò)去作為PI承擔(dān)著多項(xiàng)美國(guó)國(guó)家核酸藥研發(fā)項(xiàng)目。楊博士在核酸藥物開(kāi)發(fā)領(lǐng)域的創(chuàng)新研究成果得到了同行的一致認(rèn)同。楊博士于2003年獲得美國(guó)德克薩斯大學(xué)醫(yī)學(xué)院James W. McLaughlin 獎(jiǎng)，以表彰他發(fā)現(xiàn)抗西尼羅病毒核酸藥；楊博士于2005 和2006 連續(xù)兩年獲得紐約科學(xué)院獎(jiǎng)學(xué)金；2012年獲得國(guó)際核酸藥物學(xué)會(huì)設(shè)立的首屆青年科學(xué)家獎(jiǎng)；2017被選為北京大學(xué)醫(yī)學(xué)部?jī)?yōu)秀校友。2022年被選為蘇州工業(yè)園區(qū)創(chuàng)新領(lǐng)軍人才。在過(guò)去15年間，楊博士100多次應(yīng)邀出席各種大學(xué)、研究所、醫(yī)藥公司和國(guó)際生物醫(yī)藥舉辦的各類(lèi)會(huì)議，并做報(bào)告。楊博士先后在國(guó)際生物科技領(lǐng)域權(quán)威期刊發(fā)表了70多篇學(xué)術(shù)論文和100多篇學(xué)術(shù)會(huì)議論文摘要。楊博士已獲得三項(xiàng)美國(guó)專(zhuān)利和一項(xiàng)澳大利亞專(zhuān)利，還有多項(xiàng)專(zhuān)利正在審批中。楊博士早年獲得北京醫(yī)科大學(xué)學(xué)士和醫(yī)學(xué)碩士、歐洲博士、 美國(guó)工商管理碩士學(xué)位。 Dr. Yang has been engaged in the research and development of innovative nucleic acid drugs for more than 30 years. Prior to joining Sirnaomics, he co-founded two U.S. biotechnology companies that developed nucleic acid based therapeutics. He has served as a consultant for several international companies, a reviewer for three sections of the National Institutes of Health, a reviewer for eight international journals, and was employed as an adjunct professor at university in the United States and China from 2008 to 2018. Dr. Yang has been responsible for a number of national nucleic acid drug R&D projects in the United States as a PI in the past. Dr. Yang's achievements in the field of nucleic acid drug development have been unanimously recognized by his peers. Dr. Yang received the James W. McLaughlin Award from the University of Texas Medical Brance in 2003 for his discovery of anti-West Nile virus nucleic acid therapeuticss; Dr. Yang was awarded a fellowship to the New York Academy of Sciences for two consecutive years in 2005 and 2006; In 2012, he won the first Young Investigator Award established by the Oligonucleotide Therapeutic Society; In 2017, he was selected as an excelent alumnus of Peking University Health Science Center. In 2022, he was selected as the innovation leader of Suzhou Industrial Park. In the past 15 years, Dr. Yang has been invited to attend and give more than 100 conferences held by universities, research institutes, pharmaceutical companies and international biomedicine. Dr. Yang has published more than 70 academic papers and more than 100 abstracts of academic conference papers in authoritative international biotechnology journals. Dr. Yang has been granted three U.S. patents and one Australian patent, with several patents pending. Dr. Yang received his bachelor's and master's degrees in medicine from Beijing Medical University, his Ph.D. in Europe, and his MBA.
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 首席醫(yī)學(xué)官
所屬公司： 勁方醫(yī)藥科技有限公司
個(gè)人簡(jiǎn)介：
汪裕博士1995年畢業(yè)于同濟(jì)醫(yī)科大學(xué)（武漢）臨床醫(yī)學(xué)系。1995-2000年，在上海醫(yī)科大學(xué)（現(xiàn)復(fù)旦大學(xué)醫(yī)學(xué)院）研究生院外科學(xué)系攻讀博士學(xué)位 (附屬中山醫(yī)院普外科膽道外科)。 2000年7月畢業(yè)后在華東醫(yī)院外科短暫工作。2001年至2004年間，在美國(guó)密歇根州Wayne State University醫(yī)學(xué)院Barbara 腫瘤研究所進(jìn)行腫瘤治療領(lǐng)域的博士后研究，在相關(guān)學(xué)術(shù)雜志發(fā)表多篇文章。2004年回國(guó)后，先后在三維生物，禮來(lái)制藥，葛蘭素和賽諾菲亞太研發(fā)中心擔(dān)任腫瘤領(lǐng)域醫(yī)學(xué)負(fù)責(zé)人從事腫瘤藥物的臨床開(kāi)發(fā)。2013-2016年，在諾華生物醫(yī)學(xué)研究院臨床腫瘤轉(zhuǎn)化醫(yī)學(xué)部門(mén)作為全球早期臨床項(xiàng)目和試驗(yàn)的負(fù)責(zé)人，進(jìn)行腫瘤產(chǎn)品臨床早期研究，領(lǐng)導(dǎo)了數(shù)個(gè)first-in-class腫瘤靶向產(chǎn)品在全球的臨床研究。汪裕博士于2016年11月-2017年12月作為首席科學(xué)官就職于博納西亞醫(yī)藥科技有限公司。2018年1月創(chuàng)立詳妍咨詢(xún)，曾兼任國(guó)內(nèi)多個(gè)上市醫(yī)藥公司、生物技術(shù)公司及學(xué)術(shù)研究機(jī)構(gòu)高級(jí)醫(yī)學(xué)顧問(wèn)、外聘專(zhuān)家，和譽(yù)生物首席醫(yī)學(xué)官。2020年至今任勁方醫(yī)藥首席醫(yī)學(xué)官。
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 董事長(zhǎng)/CEO
所屬公司： 海創(chuàng)藥業(yè)股份有限公司
個(gè)人簡(jiǎn)介：
海創(chuàng)藥業(yè)股份有限公司創(chuàng)始人、董事長(zhǎng)兼總經(jīng)理（總裁），四川大學(xué)特聘教授、博士生導(dǎo)師、瑞士洛桑大學(xué)化學(xué)博士，美國(guó)斯克利普斯研究所博士后研究員、國(guó)家級(jí)人才專(zhuān)家、四川省杰出人才、成都天府海智計(jì)劃專(zhuān)家、成都高新區(qū)金熊貓成就獎(jiǎng)獲得者、成都蓉漂計(jì)劃引進(jìn)人才，四川省第九批學(xué)術(shù)與技術(shù)帶頭人。世界500強(qiáng)艾伯維（Abbvie）制藥、拜耳制藥(Bayer)美國(guó)研究院等近20年藥物研發(fā)經(jīng)驗(yàn)。曾任白鷺醫(yī)藥技術(shù)（上海）有限公司首席科技官，成都睿智化學(xué)研究有限公司總經(jīng)理，推動(dòng)10個(gè)新藥項(xiàng)目分別進(jìn)入IND申報(bào)、I-III期臨床研究階段。共發(fā)表專(zhuān)利60余篇，論文70余篇。Founder and Chief Executive Officer of Hinova Pharmaceuticals Inc. ?Past General Manager, Chengdu ChemPartner Co.Ltd., China?Past Vice President of Medicinal Chemistry, Shanghai ChemPartner Co.Ltd., China-Past Chief ScientificOfficer, Egret Pharma (Shanghai)Ltd, Shanghai, China?Past Senior Scientistll and project leader, Bayer Healthcare, Pharmaceutical product Division, USA.PastSenior Research Scientist,AbbVie, Abbott Park, Pharmaceutical Product Division, USA?Inventor and co-inventor of more than 20 compounds that are in Phase l,ll and ll clinical trials(influenzaneuraminidase inhibitor, VEGFR inhibitor, SGLT2 inhibitor,AR inhibitor).
發(fā)布時(shí)間: 2023 - 06 - 25
點(diǎn)擊次數(shù): 0
所屬職位： 首席科學(xué)官
所屬公司： 艾美斐生物醫(yī)藥有限公司
個(gè)人簡(jiǎn)介：
王建飛  博士 南京艾美斐生物醫(yī)藥科技有限公司 首席科學(xué)官 比較醫(yī)學(xué)高級(jí)醫(yī)師，國(guó)際AAALAC認(rèn)可委員會(huì)常務(wù)理事，中科院上海生命科學(xué)研究院教授（兼），上海科學(xué)院特聘教授。加拿大卡爾加里大學(xué)分子細(xì)胞學(xué)博士學(xué)位，在美國(guó)哈佛大學(xué)醫(yī)學(xué)院從事博士后研究。 曾任美國(guó)賓夕法尼亞大學(xué)比較醫(yī)學(xué)住院醫(yī)師4年，并獲執(zhí)醫(yī)資質(zhì)，任加拿大艾爾伯塔大學(xué)醫(yī)學(xué)院外科系教授。 曾擔(dān)任GSK中國(guó)研發(fā)中心整合生物技術(shù)科研部負(fù)責(zé)人，建立了完整的臨床前研發(fā)平臺(tái)，為公司的數(shù)十個(gè)項(xiàng)目提供靶點(diǎn)驗(yàn)證、先導(dǎo)化合物優(yōu)化、藥效學(xué)和藥代動(dòng)力學(xué)研究提供科學(xué)及技術(shù)支持，獲得GSK中國(guó)研發(fā)中心包括金獎(jiǎng)在內(nèi)的多次表彰，GSK全球整合生物平臺(tái)科研部領(lǐng)導(dǎo)之一, 并成功地推動(dòng)多個(gè)新藥研發(fā)項(xiàng)目完成臨床申報(bào)，進(jìn)入臨床試驗(yàn)，被評(píng)為高級(jí)GSK研究員（Senior GSK Fellow，公司科研最高級(jí)別學(xué)者）。在轉(zhuǎn)化醫(yī)學(xué)研究方面擁有超過(guò)28年的經(jīng)驗(yàn)，在世界著名的國(guó)際期刊上發(fā)表了70多篇論文，10多篇書(shū)刊章節(jié)，獲多項(xiàng)專(zhuān)利。Dr. Jianfei WangChief Scientific Officer (CSO), Member of the BoardSenior Physician in Comparative Medicine Professor of CAS Shanghai Institute of Biological Sciences (adjunct)Honorary Head and Professor, Institute of Translational Medicine, Shanghai Academy of SciencesDistinguished professor of Yunnan Agricultural UniversityDr. Wang received a Ph.D. in Molecular Cell Biology from the University of Calgary, Canada and completed his residency in Comparative Medicine at the University of Pennsylvania, USA. He then pursued his postdoctoral research at Harvard Medical School. He was later appointed as a faculty member in the Department of Surgery at the Faculty of Medicine at the University of Alberta, Canada, before returning to China.Dr. Wang is a seasoned executive with solid knowledge of both small and large molecule drugs and extensive experience in program insight for shaping R&D strategy. He has over 28 years of translational medicine research and team management experience in multinational pharmaceutical companies. At GSK R&D China, Dr. Wang established an integrated preclinical platform that provided support for target identification, validation, lead compound optimization, DMPK studies, discovery histopathology, safety assessment, and blood-brain barrier penetration for many projects that proceeded to candidate selections and clinical trials. Due to his distinguished contributions, Dr. Wang received many awards from GSK R&D China. He also served as a core member of the GSK global translational medicine leadership team and was elected as a Senior GSK Fellow, the highest level of scientific research scholar.Dr. Wang’s contributions to translational medicine & drug discovery are recognized by being granted numerous distinguished awards, including an outstanding scientist by numerous national and international organizations. He has published more than 70 papers in prestigious international journals and owns multiple patents.
微信公眾號(hào)
領(lǐng)導(dǎo)者網(wǎng)絡(luò)APP
Copyright ?2005 - 2017上海士研管理咨詢(xún)有限公司
犀牛云提供企業(yè)云服務(wù)